Please visit our MS learning channel on Youtube, providing you with hundreds of our education programs, filled with ms related topics that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll to Review all the resources found on the left side of this blog site. Use our 'search by topic' tool, when wanting to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

==================================

Monday, December 14, 2009

Could Novartis be first to launch Multiple Sclerosis oral therapy?

Article source: MSRC-UK

FTY720 (Fingolimod) is the first in a new class of disease-modifying treatments called sphingosine 1-phosphate receptor (S1P-R) modulators and has a novel mode of action different from all currently marketed MS therapies.
============================================

Novartis AG is jockeying with German drug maker Merck KgaA to deliver the first disease modifying treatment for relapsing forms of multiple sclerosis that can be taken orally, rather than by infusion or injection.

Fingolimod could finally move ahead in the race to market, as the FDA rejected Merck's new drug application for its Cladribine tablet.

On November 30, US regulators issued a "refusal to file letter" to Merck Serono, the US subsidiary. Company spokesman Gangolf Schrimpf told me the FDA preliminary action of the cladribine submission was not an assessment of the efficacy and safety of the compound. Nonetheless, the agency obviously felt the deficiencies in the filing were material enough - scientific or legal - to delay its formal review of the tablet.

Initial results from Novartis' two-year FREEDOMS FTY-720 study show that once-daily oral fingolimod reduced the relapse rate by 54 percent for the 0.5 mg dose in patients with relapsed MS. Novartis looks to file its new drug application with the FDA within next few months, followed fast track approval and launch in summer 2010.

Continue to read , direct from the MSRC-UK website

---------------------------------------------------------------------

Register at www.msviewsandnews.org to keep up-to-date with MS news and enable you to receive our weekly MS related e-newsletter

...........................................................................

1 comment:

Erin said...

Not as good as Tysabri in regards to efficacy, but better than the injectibles. Good to know!